No benefit in primary prevention trials? [7]

Pharmaceutical Journal

Volumn 272, Issue 7305, 2004, Pages 804-

  Mann, Stephen ^a   Cottrell, Jeremy ^a  

^a J/J MSD Consumer Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDICAL SOCIETY; MYOSITIS; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; STROKE; UNITED KINGDOM;

EID: 3242738499     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Journal of the American Medical Association 1998,279:1615-22.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hyperchlolesterolemia. New England Journal of Medicine 1995;333:1301-7.
3. Sever P, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and strokes events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial. Lancet 2003;361:1149-58.
4. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
5. Law M, Wald N, Rudnicka A. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke, systematic review and meta-analysis. BMJ 2003;326:1423-9.
6. Wood D, Durrington P, McInnes G, Poulter N, Rees A, Wray R. Joint British recommendations of prevention of coronary heart disease in clinical practice. Heart 1998;80(suppl 2):S1-29.
7. Scottish Intercollegiate Guidelines Network. Lipids and the Primary Prevention of Coronary Heart Disease: A National Clinical Guideline. SIGN Publication No. 40, September 1999.
8. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of Human Hypertension 2004;18:139-85.
9. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2003;24:1601-10.
10. Department of Health. National Service Framework for Coronary Heart Disease. London: The Department; March 2000.
11. Fodor JG, Frohlich JJ, Genest JJG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Canadian Medical Association Journal 2000;162:1441-7.